15 recruiting, 10 completed, 5 active not recruiting, 2 not yet recruiting. 13 Phase 2, 7 Not applicable, 6 Phase 1, 4 Phase 3, 3 Early Phase 1.
Follow Low-grade Glioma: new trials by email Literature Review of Low-grade Glioma trials Research Report on Low-grade Glioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG 18F-Fluciclovine - Glioma, Low-grade Glioma | Early Phase 1 | Recruiting | Children's Hospital of Philadelphia | 30 | 2026-11-29 | 2026-09-22 |
| Neurocognitive Assessment CNSL and LGG Digital Cognitive Assessment (TestMyBrain and Mobile Toolbox), Traditional Neuropsychological Testing, Quality of Life and Mood Questionnaires - PCNSL, Brain Tumor | Not applicable | Not yet recruiting | Dana-Farber Cancer Institute | 36 | 2026-09-01 | 2026-07-17 |
| Low-grade Gliomas in Argentina: Incidence, Survival, and Therapeutic Strategies Low-grade Glioma | Recruiting | Hospital Italiano de Buenos Aires | 40 | 2026-04-01 | 2026-06-08 | |
| Efficacy of Laser Interstitial Thermal Therapy in Young Persons With Low-grade Glioma Laser Interstitial Thermal Therapy (LITT), Magnetic resonance imaging (MRI), Questionnaires - Low-grade Glioma, Recurrent Low Grade Glioma | Not applicable | Recruiting | University of California, San Francisco | 40 | 2026-03-25 | 2026-04-01 |
| A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours Tovorafenib - Low-grade Glioma | Phase 1 | Active not recruiting | Ipsen | 6 | 2026-03-10 | 2026-10-01 |
| Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas Dabrafenib, Trametinib, Magnetic Resonance Imaging (MRI) - BRAF V600 Mutation, Low-grade Glioma | Phase 2 | Recruiting | University of California, San Francisco | 96 | 2025-11-07 | 2026-10-26 |
| HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer) HOBSCOTCH-CA - Brain Cancer, Brain Tumor | Not applicable | Recruiting | Dartmouth-Hitchcock Medical Center | 125 | 2025-11-03 | 2025-11-21 |
| FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration Luvometinib, Chemotherapeutic Agent COG-V/C Carboplatin + Vindesine, Carboplatin, Temozolomide - Low-grade Glioma, Pediatric Low-grade Gliomas | Phase 3 | Not yet recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 102 | 2025-06-30 | 2025-06-04 |
| FG001 in Subjects with Meningiomas or Presumed Low-Grade Gliomas Scheduled for Neurosurgery FG001 prior to surgery - Low-grade Glioma, Meningioma | Phase 2 | Unknown | Copenhagen University Hospital, Rigshospitalet | 40 | 2024-05-01 | 2024-11-12 |
| Monitoring of Patients With Low-grade Gliomas Using Circulating miRNA Blood sample - Glioma, miRNA | Recruiting | University Hospital, Caen | 20 | 2024-04-25 | 2024-09-24 | |
| Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas Tovorafenib, Vinblastine - Low-grade Glioma | Early Phase 1 | Recruiting | Daniel Morgenstern | 57 | 2024-03-21 | 2025-05-15 |
| A Study of Avutometinib for People With Solid Tumor Cancers Avutometinib - Refractory Cancer, CNS Tumors | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 3 | 2023-10-20 | 2026-11-04 |
| Niraparib In Recurrent IDH 1/2 Gliomas Niraparib, Resection/Treatment with Niraparib - Low-grade Glioma, IDH2 Gene Mutation | Early Phase 1 | Active not recruiting | Massachusetts General Hospital | 16 | 2023-05-18 | 2026-07-24 |
| Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume) Binimetinib 15 MG - Low-grade Glioma, Pancreatic Cancer | Phase 2 | Recruiting | National Cancer Center, Japan | 32 | 2023-03-29 | 2023-12-13 |
| DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) Tovorafenib, Chemotherapeutic Agent - Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma | Phase 3 | Active not recruiting | Day One Biopharmaceuticals, Inc. | 418 | 2023-02-27 | 2026-10-19 |
| CEST in Low-grade Glioma Study Saturation Transfer (ST)-MRI - Low-grade Glioma | Not applicable | Recruiting | Sunnybrook Health Sciences Centre | 100 | 2022-08-12 | 2023-08-18 |
| GROW (Glioma Specialists Reaching Out With Support) Support GROW (Glioma Specialists Reaching Out With Support) Support Program - Low-grade Glioma, Survivorship | Not applicable | Withdrawn | Dana-Farber Cancer Institute | 2022-07-01 | 2023-01-05 | |
| Evaluation of Cognitive and Motor Neurological Disorders in the Short and Long Term After Surgery for the Removal of a Diffuse Low-grade Glioma of the Supplementary Motor Area Test battery - Cognitive Disorders, Motor Disorders | Completed | University Hospital, Tours | 22 | 2022-05-19 | 2022-09-07 | |
| A Living Tissue Bank of Patient-Derived Organoids From Glioma Tumors Low-grade Glioma, High Grade Glioma | Recruiting | Maastricht Radiation Oncology | 50 | 2022-05-01 | 2026-01-27 | |
| A Phase II Trial of Poly-ICLC for Low-Grade Gliomas Poly ICLC - NF1, Low-grade Glioma | Phase 2 | Terminated | University of Alabama at Birmingham | 3 | 2022-02-08 | 2025-03-21 |
Showing 20 of 38. Sign in to see all of them.
Glioma (16) · Brain Neoplasms (6) · Cognitive Dysfunction (4) · Astrocytoma (3) · Glioblastoma (3) · Neoplasms (3) · Caregiver Burden (2) · Meningioma (2) · Neurofibroma, Plexiform (2) · Oligodendroglioma (2) · Central Nervous System Neoplasms (1) · Diffuse Intrinsic Pontine Glioma (1) · Disease Progression (1) · Ganglioglioma (1) · Ganglioneuroma (1)
Neoplasms (20) · Neoplasms by Histologic Type (20) · Neoplasms, Germ Cell and Embryonal (20) · Neoplasms, Glandular and Epithelial (20) · Neoplasms, Nerve Tissue (20) · Neuroectodermal Tumors (20) · Neoplasms, Neuroepithelial (19) · Neoplasms by Site (12) · Nervous System Diseases (11) · Nervous System Neoplasms (11) · Brain Diseases (10) · Central Nervous System Diseases (10) · Central Nervous System Neoplasms (10) · Brain Neoplasms (4) · Cognition Disorders (4)
tovorafenib (6) · Temozolomide (4) · Carboplatin (3) · trametinib (3) · Everolimus (2) · Magnetic Resonance Spectroscopy (2) · Vinorelbine (2) · Allied Health Personnel (1) · Antineoplastic Agents (1) · Bevacizumab (1) · Blood Specimen Collection (1) · Irinotecan (1) · Mebendazole (1) · Neuropsychological Tests (1) · Palliative Care (1)
University of California, San Francisco (4) · Dana-Farber Cancer Institute (3) · Day One Biopharmaceuticals, Inc. (3) · Beijing Sanbo Brain Hospital (1) · Centre Oscar Lambret (1) · Children's Hospital of Philadelphia (1) · Copenhagen University Hospital, Rigshospitalet (1) · Daniel Morgenstern (1) · Dartmouth-Hitchcock Medical Center (1) · Eugene Hwang (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Hospital Italiano de Buenos Aires (1) · Hospital del Rio Hortega (1) · Ipsen (1) · Julie Krystal (1)
United States (17) · France (7) · Canada (5) · Denmark (4) · Netherlands (4) · Australia (3) · China (3) · Germany (3) · Italy (3) · Spain (3) · Switzerland (3) · United Kingdom (3) · Austria (2) · Belgium (2) · Israel (2)
Anna Vinitsky, MD, MS (1) · Daniel Morgenstern (1) · Elaine T Kiriakopoulos, MD, MPH, MSc (1) · Eugene Hwang, MD (1) · Giles W. Robinson, MD (1) · Greg J Stanisz, PhD (1) · Isabel Arrillaga-Romany, MD, Phd (1) · Ivan Alfredo Huespe, MD, MPh (1) · Jennie Taylor, MD, MPH (1) · Julie Krystal, MD (1) · Juliette Southworth, BS, CCRP (1) · Karen D. Wright, MD (1)
PMID 31881853, PMID 33442748, PMID 37978284, PMID 38291372, PMID 38413458, PMID 41198344
P50CA165962 (1)